Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT01076153
First received: February 24, 2010
Last updated: July 1, 2011
Last verified: June 2011
Results First Received: April 22, 2011  
Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Condition: Respiratory Tract Infection
Intervention: Drug: Clarithromycin (Klacid® MR)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 760 participants were enrolled in the study. 694 were analyzed as 66 participants had protocol deviations (some more than 1): Age less than 18 years (22), took excluded drugs (17), took Klacid more than 14 days (16), took Klacid less than 5 days (11), added 250 mg Klacid to Klacid MR (5), and used injectable drugs (3).

Reporting Groups
  Description
Klacid MR Male or female Thai adults with upper and/or lower respiratory tract infections taking Klacid (clarithromycin) modified release (MR) 500 mg according to the Prescribing Information.

Participant Flow:   Overall Study
    Klacid MR
STARTED   760 
COMPLETED   749 
NOT COMPLETED   11 
Symptoms improved/resolved                10 
Adverse Event                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Klacid MR The per-protocol population (694 participants) of male or female Thai adults with upper and/or lower respiratory tract infections on Klacid MR.

Baseline Measures
   Klacid MR 
Overall Participants Analyzed 
[Units: Participants]
 694 
Age [1] 
[Units: Years]
Mean (Standard Deviation)
 41.16  (14.22) 
[1] Based on per-protocol population (694 participants).
Age, Customized [1] 
[Units: Participants]
 
18 to 20 years   28 
21 to 30 years   154 
31 to 40 years   204 
41 to 50 years   141 
51 to 60 years   102 
Over 60 years   65 
[1] Based on per-protocol population (694 participants).
Gender [1] 
[Units: Participants]
 
Female   404 
Male   290 
[1] Based on per-protocol population (694 participants).
Region of Enrollment [1] 
[Units: Participants]
 
Thailand   694 
[1] Based on per-protocol population (694 participants).
Diagnosis [1] 
[Units: Participants]
 
Upper respiratory tract infection   510 
Lower respiratory tract infection   165 
Both upper and lower respiratory tract infections   19 
[1] Participant diagnosis at study entry for the per-protocol population (694 participants).
Risk factor: Smoking status [1] 
[Units: Participants]
 
Participant was a smoker   164 
Participant did not smoke   530 
[1] Whether or not participants smoked cigarettes for the per-protocol population (694 participants).


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Average Time From Baseline to Recovery From Cough and Other Symptoms   [ Time Frame: Baseline to 14 days ]

2.  Secondary:   Number and Type of Adverse Events   [ Time Frame: Baseline to 14 days ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Global Medical Services
Organization: Abbott
phone: 1-800-633-9110



Responsible Party: Savary Om/ Regional Medical Director, Abbott Laboratories
ClinicalTrials.gov Identifier: NCT01076153     History of Changes
Other Study ID Numbers: P08-331
Study First Received: February 24, 2010
Results First Received: April 22, 2011
Last Updated: July 1, 2011